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Context: The delivery of hydrocortisone through phonopho-
resis is a widely prescribed technique for the treatment of var-
ious musculoskeletal inflammatory conditions. However, limited
scientific evidence exists to support the efficacy of phonopho-
resis in delivering hydrocortisone to skeletal muscle tissue in
humans.
Objective: To determine hydrocortisone (cortisol) concentra-
tions in human skeletal muscle tissue after a phonophoresis
treatment using 10% hydrocortisone gel.
Design: Randomized design in which 12 subjects were ran-
domly assigned to either an ultrasound (sham) treatment or a
10% hydrocortisone phonophoresis treatment.
Setting: Laboratory.
Patients or Other Participants: Twelve healthy subjects
(8 women, 4 men: age  22.3  2.64 years, height  168.28
 8.19 cm, mass  69.58  9.05 kg) with no history of mus-
culoskeletal disease, preexisting inflammatory conditions, or re-
cent orthopaedic injuries.
Intervention(s): Ultrasound at 1.0 MHz, 1.0 W/cm2, at a con-
tinuous setting for 7 minutes was applied to a standardized area
of the vastus lateralis muscle in both groups. The contralateral
limb served as the control (no treatment) for both the sham and
the phonophoresis groups.
Main Outcome Measure(s): Vastus lateralis muscle biopsies
were taken from both legs immediately after treatment, and cor-
tisol concentrations were analyzed using an enzyme-linked im-
munosorbent assay.
Results: We observed no significant difference in muscle
cortisol concentration between the contralateral control limb and
the treatment limb in either the sham or the phonophoresis
group (P  .05). No significant difference was noted when the
treatment limbs in the sham and phonophoresis groups were
compared (P  .05).
Conclusions: Our data suggest that a 10% hydrocortisone-
based phonophoresis treatment did not increase cortisol con-
centrations in human skeletal muscle tissue.
Key Words: ultrasound, ELISA, inflammation, biopsy, hydro-
cortisone
Phonophoresis, a technique in which ultrasound is usedto increase the transcutaneous transmission of drugs, isa widely applied clinical technique for the treatment of
musculoskeletal inflammation. Specifically, phonophoretic de-
livery of hydrocortisone, a synthetic equivalent of the endog-
enously produced anti-inflammatory corticosteroid cortisol, is
purported to provide relief of symptoms associated with ar-
thritis, tendinitis, and bursitis.1–3 Although a few authors using
animal models (eg, porcine, canine) have provided disparate
results regarding the ability of phonophoresis to deliver hy-
drocortisone to musculoskeletal tissue,4–6 no scientific evi-
dence is currently available demonstrating the ability of phon-
ophoresis to deliver hydrocortisone to subcutaneous tissue in
humans. The paucity of literature regarding the efficacy of
phonophoresis in the delivery of drugs to subcutaneous tissues
precludes any definitive conclusions regarding its potential
usefulness in the management of inflammation in humans.
Therefore, our purpose was to examine the efficacy of
phonophoresis in the delivery of hydrocortisone to skeletal
muscle tissue in humans using commonly accepted clinical
values. A human model was chosen because (1) extraction
of skeletal muscle tissue from human subjects is a viable
approach, and (2) phonophoretic delivery of hydrocortisone
is a promising avenue for the treatment of skeletal muscle
inflammation associated with a variety of muscle traumas in
humans (eg, strains, crush induced, thermal insults). Consid-
ering the demonstrated transdermal drug delivery potential of
ultrasound,7 we hypothesized that an increase in skeletal
muscle tissue cortisol concentrations would result after a
standard hydrocortisone-based phonophoresis treatment.
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METHODS
Subjects
Twelve apparently healthy subjects (8 women, 4 men: age
 22.3  2.64 years, height  168.28  8.19 cm, mass 
69.58  9.05 kg) with no history of musculoskeletal disease,
preexisting inflammatory conditions, or recent orthopaedic in-
juries participated in the study. All subjects provided written
informed consent before participating. Procedures pertinent to
the study were performed in accordance with guidelines es-
tablished by The University of Toledo Human Subjects Re-
search and Review Committee.
Experimental Design
In a randomized design, each subject was assigned to either
an ultrasound (sham) (n  6; 4 women, 2 men) or phonopho-
resis (n  6; 4 women, 2 men) treatment group. After the
subjects were allocated to treatment groups, 1 leg was ran-
domly allocated to receive either sham or phonophoresis treat-
ment. The other leg served as the contralateral control (un-
treated) in all subjects. To control for potential diurnal
influences, all subjects reported to the laboratory between 11:00
AM and 12:00 PM. Subjects were instructed not to participate
in exercise or any excess physical activity before reporting to
the laboratory.
Treatment Settings
All ultrasound treatments (sham and phonophoresis) were
administered by the same researcher (an athletic trainer) using
an Omnisound 3000B machine (Accelerated Care Plus, Reno,
NV) with a constant transducer head speed of approximately
2.0 cm/s. A 5-cm2 sound head was used with the values at 1
MHz, 1.0 W/cm2, at a continuous setting. The treatment was
applied for 7 minutes directly over the vastus lateralis muscle,
using a 10-cm2 template to ensure that treatment remained in
the designated area. These ultrasound settings were selected
according to previous findings8–10 and are in agreement with
standard accepted clinical practice for phonophoresis admin-
istration. These treatment values were selected to capture both
the thermal and nonthermal effects of ultrasound in order to
optimize transdermal hydrocortisone delivery.11
For the sham condition, ultrasound was administered using
5 mL of Aquasonic 100 ultrasound transmission gel (Parker
Laboratories, Inc, Fairfield, NJ). For the phonophoresis treat-
ment, ultrasound was administered using 5 mL of Aquasonic
ultrasound transmission gel that was supplemented with 10%
hydrocortisone (prepared by an Ohio-licensed compounding
pharmacist). This hydrocortisone concentration was chosen to
coincide with the purported benefit of 10% hydrocortisone-
based phonophoresis treatment2 and is in accordance with cur-
rent standard clinical practice. Any excess gel was wiped away
upon completion of the treatment.
Muscle Biopsy
Before the treatment was initiated, an area of skin over the
vastus lateralis muscles bilaterally was shaved in preparation
for ultrasound administration and muscle biopsy. Immediately
after ultrasound treatment, the area was sanitized using an an-
tiseptic solution, and a small area over the belly of the vastus
lateralis muscle was then anesthetized via a subcutaneous in-
jection of 2 mL of 1% lidocaine. After 10 minutes, a muscle
biopsy, using the protocol established by Bergstrom,12 was
taken from both legs. Briefly, a sterile biopsy needle (5 mm)
was inserted through an incision of approximately 1 cm and
a muscle sample (approximately 100 mg) extracted from the
belly of the vastus lateralis.13 The order of the biopsy proce-
dure (treated versus untreated leg) was randomly determined.
Muscle samples were snap frozen in isopentane precooled with
dry ice and immediately stored at 80C for further process-
ing.
Cortisol Analysis
Muscle tissue samples were homogenized in phosphate-
buffered saline (pH  7.4) and cortisol extracted according to
manufacturer’s guidelines (Oxford Biomedical Research Inc,
Oxford, MI). Briefly, muscle homogenates were diluted 1:10
in ethyl ether and vortexed to facilitate phase separation. The
organic phase was extracted and evaporated under a stream of
nitrogen gas. The precipitate was then dissolved in 100 L of
diluted extraction buffer (Oxford Biomedical) and cortisol
measured via an enzyme-linked immunosorbent assay
(ELISA; Oxford Biomedical). All samples were analyzed in
duplicate via spectroscopy (SpectraMax 190, 650 nm; Molec-
ular Devices, Sunnyvale, CA) and average concentrations used
for statistical analyses. Samples are reported in ng/mg muscle
tissue.
Statistical Analysis
We used a paired-samples t test to analyze baseline muscle
cortisol concentrations between the contralateral control limb
and treatment limb for both the sham (ultrasound) and phono-
phoresis groups. After baseline analysis was performed, we
calculated an independent t test to analyze muscle cortisol con-
centrations between the respective treatment limbs for both the
sham and phonophoresis groups. Significance was determined
at P  .05 for all statistical procedures.
RESULTS
We observed no significant difference (P  .38) in muscle
cortisol concentrations between the contralateral control limb
and respective treatment limb in either the sham (mean 
SEM: 0.1442  0.0106 ng/mg muscle) or phonophoresis
groups (0.1428  0.0196 ng/mg muscle) (Figure). No signif-
icant difference (P  .51) in muscle cortisol concentrations
was noted when we compared the treatment limbs in the sham
(0.1263  0.0266 ng/mg muscle) and phonophoresis groups
(0.1348  0.0368 ng/mg muscle) (see Figure). All cortisol
levels fell within the accepted reference range for the ELISA
(0.04–10 ng/mL; Oxford Biomedical).
DISCUSSION
Phonophoresis has been shown to be effective for driving
low-molecular-weight compounds (eg, insulin: molecular
mass  6000 d) through the dermal layer,7,14 thus providing
a promising, noninvasive approach for the delivery of a myr-
iad of medications (eg, hydrocortisone: molecular weight 
342 d) to subcutaneous tissues. Once through the skin, how-
ever, the ability of phonophoresis to provide targeted delivery
of drugs to specific tissues is uncertain. To our knowledge,
this is the first study to address the effectiveness of phono-
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Effect of 10% hydrocortisone-based phonophoresis on skeletal
muscle tissue cortisol concentrations. The contralateral limb
served as the control (CT) for both the ultrasound (sham) and
phonophoresis (phono) groups. Data represent mean  SEM.
phoresis in the targeted delivery of anti-inflammatory medi-
cation to skeletal muscle tissue in humans. In this study, hy-
drocortisone (cortisol) concentrations in skeletal muscle tissue
after 10% hydrocortisone-based phonophoresis treatment were
not significantly elevated over concentrations after sham treat-
ment. Although previous authors4–6,15 using various animal
models have reported disparate findings on muscle cortisol
concentrations after hydrocortisone-based phonophoresis, our
findings indicate that standard phonophoresis treatment, using
the defined settings, was ineffective for the delivery of hydro-
cortisone to skeletal muscle tissue in humans.
Controversy exists within the literature regarding the effec-
tiveness of ultrasound in the delivery of cortisol into muscle
tissue. In agreement with our findings, Davick et al6 observed
no increase in muscle cortisol concentrations in canines after
phonophoresis treatment using a tritiated cortisol cream. Al-
though Davick et al indicated that the cortisol was able to
penetrate the skin, their findings did not demonstrate elevated
cortisol concentrations within the underlying skeletal muscle
tissue. We did not assess hydrocortisone penetration, but it is
conceivable that the administration of ultrasound resulted in
the penetration of cortisol into the subdermal layers surround-
ing the muscle tissue.16 Therefore, it is possible that the
phonophoresis treatment did not result in an increase in muscle
cortisol concentrations but could have been absorbed in the
extracellular environment of the muscle and redistributed
through uptake by the surrounding vasculature. However, Bare
et al15 observed no significant difference in serum cortisol con-
centrations after a 10% hydrocortisone phonophoresis treat-
ment similar to the settings we used, indicating that the drug
did not diffuse into the circulation. As a result, it is unlikely
that the phonophoresis treatment we used resulted in an in-
crease in blood cortisol concentrations.
In contrast, previous authors have demonstrated an increase
in intramuscular cortisol concentrations after phonophoresis
treatment. In landmark studies, Griffin and Touchstone4,5 ob-
served an increase in cortisol in skeletal muscle tissue after
both ultrasound and phonophoresis treatments in swine using
ultrasound intensities of 0.1, 0.3, 1.0, and 3.0 W/cm2. Gen-
erally, the observed increases in cortisol were greatest with
prolonged phonophoresis treatments (ie, 17–51 minutes) using
the lower ultrasound intensities of 0.1 and 0.3 W/cm2, indi-
cating that skin permeability may be enhanced with lower-
intensity, longer-duration ultrasound treatments.5 Provided that
these observations transcend to the human model, it is possible
that a protracted treatment of low-intensity phonophoresis may
be required to drive hydrocortisone into skeletal muscle tissue
in humans. Investigation into divergent ultrasound treatment
settings on muscle tissue cortisol concentrations after hydro-
cortisone-based phonophoresis in humans may be warranted.
Although it is evident from the present findings that hydro-
cortisone-based phonophoresis using the settings defined with-
in this study did not result in an increase in intramuscular
cortisol concentrations in humans, uninjured tissue may be re-
sistant to exogenous pharmaceutical delivery. For instance,
Cagnie et al9 found ketoprofen (a nonsteroidal anti-inflam-
matory drug) concentrations to be higher in synovial tissue
after ketoprofen-based phonophoresis treatment in patients
with knee injuries. We reasoned that hydrocortisone, being a
lipophilic molecule that can readily traverse the lipid bilayer
of cell membranes,17 should be able to access the sarcoplasm
of intact skeletal muscle cells. However, injured muscle has
been shown to demonstrate an up-regulation in glucocorticoid
receptor availability18 and an increase in cellular endocyto-
sis,19,20 which may make the muscle cells more amenable to
the effects of hydrocortisone-based phonophoresis.
Although it cannot be determined in the present study, fac-
tors such as inadequate skin hydration21 and/or suboptimal
heating of either the stratum corneum or subcutaneous tissues
might have hindered ultrasound-mediated transdermal drug
transport. The thermal influence of ultrasound on the perme-
ability of the dermal layer has received some support,22 but
Mitragotri et al7 demonstrated that the nonthermal and me-
chanical effects of therapeutic ultrasound (ie, frequency range
 1–3 MHz, intensity range  0–2 W/cm2) appear to play a
more significant role in transdermal drug delivery. Although
the ultrasound settings we used likely provided both thermal
and nonthermal effects at the cutaneous and subcutaneous lev-
els,11 the degree to which these ultrasound effects need to be
attained for targeted subcutaneous drug transmission in hu-
mans is a potential avenue of future research.
In conclusion, a diverse array of treatment strategies has
been developed to help ameliorate the purported negative side
effects associated with skeletal muscle injury and inflamma-
tion. Hydrocortisone-based phonophoresis is a widely pre-
scribed therapeutic modality that may provide transient relief
of discomfort associated with various musculoskeletal mala-
dies.1,3 In light of the present findings, however, the value of
a standard hydrocortisone-based phonophoresis treatment for
the management of skeletal muscle inflammation appears to
be debatable. More expansive studies (eg, larger sample sizes)
examining the efficacy of different ultrasound settings for drug
delivery to damaged muscle and associated tissue (eg, tendon,
bursa) may be warranted to detect any increases in skeletal
muscle cortisol elicited after phonophoresis treatment.
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